Nyrada Inc.
Nyrada Inc.
Your view on NYR.AX
Overview
What the company does, where it operates, and who runs it.
About Nyrada Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James Bonnar
- Headquarters
- Sydney Place, Sydney, NSW, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James Bonnar
- Headquarters
- Sydney Place, Sydney, NSW, AU
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases.
Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Nyrada Inc.. Starting points for Nyrada Inc.: EPS -AUD 0.03, beta 0.88 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Nyrada Inc.. Nyrada Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Nyrada Inc.. Trailing twelve-month EPS for Nyrada Inc. stands at -AUD 0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Nyrada Inc.. Nyrada Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ACW.AXActinogen Medical Limited | Healthcare | Biotechnology | — | ||
| AGN.AXArgenica Therapeutics Ltd | Healthcare | Biotechnology | — | ||
| ALA.AXArovella Therapeutics Limited | Healthcare | Biotechnology | — | ||
| ATH.AXAlterity Therapeutics Limited | Healthcare | Biotechnology | — | ||
| IXC.AXInvex Therapeutics Ltd | Healthcare | Biotechnology | — | ||
| NEU.AXNeuren Pharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| NSB.AXNeuroScientific Biopharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| NTI.AXNeurotech International Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ORGSOrgenesis Inc. | Healthcare | OTC | $3.0M | ||
| ORICORIC Pharmaceuticals, Inc. | Healthcare | NASDAQ | $795.1M | ||
| ORKAOruka Therapeutics, Inc. | Healthcare | NASDAQ | $6.5B | ||
| ORMPOramed Pharmaceuticals Inc. | Healthcare | NASDAQ | $169.2M | ||
| ORPOFOSE Immunotherapeutics S.A. | Healthcare | OTC | $260.3M | ||
| ORYZFOryzon Genomics S.A. | Healthcare | OTC | $283.9M | ||
| OSRHWOSR Holdings, Inc. | Healthcare | NASDAQ | $7.8M | ||
| OSTXOS Therapies Incorporated | Healthcare | AMEX | $48.1M | ||
| OTLCOncotelic Therapeutics, Inc. | Healthcare | OTC | $21.2M | ||
| OTLKOutlook Therapeutics, Inc. | Healthcare | NASDAQ | $99.3M | ||
| OVIDOvid Therapeutics Inc. | Healthcare | NASDAQ | $426.5M | ||
| OXBOFOxford BioDynamics Plc | Healthcare | OTC | $4.3M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Nyrada Inc.. Coverage tracks Nyrada Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Nyrada Inc.